Global Autoimmune Disease Diagnosis Market- By Product, By End User, By Test Type - Regional Outlook, Competitive Strategies and Segment Forecasts to 2030

Description

According to SPER Market Research, the Global Autoimmune Disease Diagnosis Market is estimated to reach USD 8.36 billion by 2030 with a CAGR of 7.8%.

A body's aberrant immune response that results in the development of antibodies that target its own cells and tissues, causing degeneration and the elimination of healthy tissues, is referred to as an autoimmune illness. Multiple sclerosis, type 1 diabetes, and rheumatoid arthritis are three of the almost 80 autoimmune disorders that are prevalent globally.

Autoantibody, antinuclear, complete blood count, C-reactive protein, and erythrocyte sedimentation rate tests are used to identify the autoimmune disease. Growing incidences of conditions like rheumatoid arthritis and Hashimoto's thyroiditis, as well as the existence of supportive governmental regulations, will have a significant impact on the market growth for autoimmune disease diagnostics.

Impact of COVID-19 on the Global Autoimmune Disease Diagnosis Market:

An international stress test has been created by the COVID-19 epidemic. Worldwide, the COVID-19 illness has affected 545 million individuals. According to the most recent data from the Worldometers, the death toll has reached 6,464,291 globally (as of August 18, 2022). The number is continually increasing, and it's still hard to determine how long the epidemic will last. Global concern and a sense of urgency have been brought on by the COVID-19 epidemic. To combat the coronavirus, several nations have implemented rigorous measures, including mass vaccination campaigns, social withdrawal, the usage of masks, etc. Manufacturers in the autoimmune disease diagnostics market are concentrating on creating cutting-edge technologies for performing the most tests in the shortest amount of time. As a result, we anticipate that physicians will notice an increase in the number of patients, which will fuel the expansion of the autoimmune disorders diagnostics market.

Scope of the report:

Market size available for years 2019-2030

Base year considered 2021

Forecast period 2022-2030

Segments covered By Product, By End User, By Test Type

Geographies covered North America, Europe, Asia Pacific, South America, Middle East and Africa

Companies Covered Abbott Laboratories Inc., Bio-Rad Laboratories, bioMerieux SA, Danahar Corp., F. Hoffmann-La Roche AG, Labcorp Acquires Assets of Myriad Genetics, Merck and co. Acquired Pandion Therapeutics, Oncimmune Acquires Protagen Diagnostics, PerkinElmer Acquires Euroimmune, Quest Diagnostics Acquires Labtech Diagnostics, Sebia Acquires ORGENTEC Diagnostika, Siemens Healthineers, Thermo Fisher Scientific Inc.

Global Autoimmune Disease Diagnosis Market, By Product:

Based on the Product, Global Autoimmune Disease Diagnosis Market is segmented as; Consumables and Assay Kits, Instruments.

Global Autoimmune Disease Diagnosis Market, By End User:

Based on the End User, Global Autoimmune Disease Diagnosis Market is segmented as; Clinical Laboratories and Hospitals.

Global Autoimmune Disease Diagnosis Market, By Test Type:

Based on the Test Type, Global Autoimmune Disease Diagnosis Market is segmented as; Routine Laboratory Tests, Autoantibodies Tests, Immunologic Tests and Other Tests.

Global Autoimmune Disease Diagnosis Market, By Region:

Europe and Asia held the highest share of the worldwide Global Autoimmune Disease Diagnosis Market, but it is predicted to develop slowly throughout the forecast period. Because of its size, it remains one of the most important marketplaces for Autoimmune Disease Diagnosis companies.

Product Code: MEDE2207

1. Introduction

1.1 Scope of the report
1.2 Market segment analysis

2. Research Methodology

2.1 Research data source
- 2.1.1 Secondary data
- 2.1.2 Primary data
- 2.1.3 SPER's internal database
- 2.1.4 Premium insight from KOL's
2.2 Market size estimation
- 2.2.1 Top-down and Bottom-up approach
- 2.2.2 Data triangulation

3. Executive Summary

4. Market Dynamics

4.1 Driver, Restraint, Opportunity, and Challenges analysis
- 4.1.1 Drivers
- 4.1.2 Restraints
- 4.1.3 Opportunities
- 4.1.4 Challenges
4.2 COVID-19 Impacts on Global Autoimmune Disease Diagnosis Market

5. Market variables and outlook

5.1 SWOT analysis
- 5.1.1 Strengths
- 5.1.2 Weaknesses
- 5.1.3 Opportunities
- 5.1.4 Threats
5.2 PESTEL analysis
- 5.2.1 Political landscape
- 5.2.2 Economic landscape
- 5.2.3 Social landscape
- 5.2.4 Technological landscape
- 5.2.5 Environmental landscape
- 5.2.6 Legal landscape
5.3 PORTER'S five forces analysis
- 5.3.1 Bargaining power of suppliers
- 5.3.2 Bargaining power of Buyers
- 5.3.3 Threat of Substitute
- 5.3.4 Threat of new entrant
- 5.3.5 Competitive rivalry
5.4 Heat map analysis

6. Global Autoimmune Disease Diagnosis Market, By Product, 2019-2030 (USD Million)

6.1 Consumables and Assay Kits
6.2 Instruments

7. Global Autoimmune Disease Diagnosis Market, By End User, 2019-2030 (USD Million)

7.1 Clinical Laboratories
7.2 Hospitals
7.3 Others

8. Global Autoimmune Disease Diagnosis Market, By Test Type, 2019-2030 (USD Million)

8.1 Routine Laboratory Tests
8.2 Autoantibodies Tests
8.3 Immunologic Tests
8.4 Other Tests

9. Global Autoimmune Disease Diagnosis Market, By Region, 2019-2030 (USD Million)

9.1 North America
- 9.1.1 United States
- 9.1.2 Canada
- 9.1.3 Mexico
9.2 Europe
- 9.2.1 Germany
- 9.2.2 United Kingdom
- 9.2.3 France
- 9.2.4 Italy
- 9.2.5 Spain
- 9.2.6 Rest of Europe
9.3 Asia-Pacific
- 9.3.1 China
- 9.3.2 Japan
- 9.3.3 India
- 9.3.4 Australia
- 9.3.5 South Korea
- 9.3.6 Rest of Asia-Pacific
9.4 South America
- 9.4.1 Brazil
- 9.4.2 Argentina
- 9.4.3 Rest of South America
9.5 Middle East & Africa
- 9.5.1 Kingdom of Saudi Arabia
- 9.5.2 United Arab Emirates
- 9.5.3 Rest of Middle East & Africa

10. Company Profiles

10.1 Abbott Laboratories
- 10.1.1 Company details
- 10.1.2 Financial outlook
- 10.1.3 Product summary
- 10.1.4 Recent developments
10.2 Bio-Rad Laboratories Inc.
- 10.2.1 Company details
- 10.2.2 Financial outlook
- 10.2.3 Product summary
- 10.2.4 Recent developments
10.3 bioMerieux SA
- 10.3.1 Company details
- 10.3.2 Financial outlook
- 10.3.3 Product summary
- 10.3.4 Recent developments
10.4 Danaher Corp.
- 10.4.1 Company details
- 10.4.2 Financial outlook
- 10.4.3 Product summary
- 10.4.4 Recent developments
10.5 F. Hoffmann-La Roche AG
- 10.5.1 Company details
- 10.5.2 Financial outlook
- 10.5.3 Product summary
- 10.5.4 Recent developments
10.6 Labcorp Acquires Assets of Myriad Genetics
- 10.6.1 Company details
- 10.6.2 Financial outlook
- 10.6.3 Product summary
- 10.6.4 Recent developments
10.7 Merck & Co. Acquired Pandion Therapeutics
- 10.7.1 Company details
- 10.7.2 Financial outlook
- 10.7.3 Product summary
- 10.7.4 Recent developments
10.8 Oncimmune Acquires Protagen Diagnostics
- 10.8.1 Company details
- 10.8.2 Financial outlook
- 10.8.3 Product summary
- 10.8.4 Recent developments
10.9 PerkinElmer Acquires Euroimmune
- 10.9.1 Company details
- 10.9.2 Financial outlook
- 10.9.3 Product summary
- 10.9.4 Recent developments
10.10 Quest Diagnostics Acquires Labtech Diagnostics
- 10.10.1 Company details
- 10.10.2 Financial outlook
- 10.10.3 Product summary
- 10.10.4 Recent developments
10.11 Sebia Acquires ORGENTEC Diagnostika
- 10.11.1 Company details
- 10.11.2 Financial outlook
- 10.11.3 Product summary
- 10.11.4 Recent developments
10.12 Siemens Healthineers
- 10.12.1 Company details
- 10.12.2 Financial outlook
- 10.12.3 Product summary
- 10.12.4 Recent developments
10.13 Thermo Fisher Scientific Inc.
- 10.13.1 Company details
- 10.13.2 Financial outlook
- 10.13.3 Product summary
- 10.13.4 Recent developments